Lilly ly3475070
NettetLY-3475070 (LY3475070; LY 3475070) is a novel, potent, oral and selective CD73 inhibitor (cluster of differentiation 73, IC50 = 28 nM) with potential anticancer activity. Nettet4. nov. 2024 · A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. ... Eli Lilly and Company ) 2024 …
Lilly ly3475070
Did you know?
NettetUne étude de l'inhibiteur de CD73 LY3475070 seul ou en association avec le pembrolizumab chez des participants atteints d'un cancer avancé Une première mondiale multicentrique de phase 1 dans l'étude humaine de l'inhibiteur de CD73 LY3475070 en monothérapie ou en association avec le pembrolizumab chez des patients atteints de … NettetEine weltweit erste multizentrische Phase-1-Studie am Menschen mit dem CD73-Inhibitor LY3475070 als Monotherapie oder in Kombination mit Pembrolizumab bei Patienten mit fortgeschrittenen soliden malignen Erkrankungen Sponsoren: Hauptsponsor: Eli Lilly und Co Mitarbeiter: Merck Sharp & Dohme LLC Quelle: Eli Lilly and Company
NettetCD73 inhibitor LY3475070 targets and binds to CD73, leading to clustering of and internalization of CD73. Nettet1. jul. 2024 · Abstract. Background: Patients (pts) with EGFRm T790M-negative NSCLC with progressive disease (PD) on an EGFR TKI have limited therapy options. CD73 …
Nettet1. aug. 2024 · CD73 is a multifunctional ectoenzyme affecting both tumor cells and immune cells. CD73 has been hijacked by TME to promote tumor growth and metastasis. Targeting CD73 and other adenosinergic molecules orchestrates anti-tumor immunity. CD73 blockade achieves synergy in combination with conventional therapy and/or ICB. Nettet4. nov. 2024 · A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. ... Eli Lilly and Company. Study Details; Tabular View; No Results Posted; Disclaimer; How to Read a Study Record; No Study Results Posted on ClinicalTrials.gov for this Study
NettetThe reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer. The ... Eli Lilly and Company: Start date: January 2024: End date: May 2024: Enrollment: 52 participants: Identifiers: NCT04148937, 17504, J2I-MC-JZMA, 2024-003270-64, …
NettetLY3475070 Alone or in Combination With Pembrolizumab is now under trials for patients with Advanced Cancer. Chemical Structure LY-3475070. CAS# 2375815-63-5. Product … dメニュー 遅いNettetHovedsponsor: Eli Lilly and Company Samarbeider: Merck Sharp & Dohme LLC Kilde: Eli Lilly and Company Kort oppsummering: Årsaken til denne studien er å se om CD73 … dメニュー 開くNettet30. jan. 2024 · Eli Lilly cuts 3 cancer drugs amid Q4 clear-out. It’s that time of year when Big Pharmas are reporting revenues and zeroing in on the pipeline updates they want … dメニュー 課金 解約Nettet10. mar. 2024 · Active, not recruiting. A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. Sign in Get a demo Search. ... Eli Lilly and Company (Industry) Overall Status. Active, not recruiting. CT.gov ID NCT04148937. d モーニングNettetDrug: LY3475070 Drug: Pembrolizumab: Advanced Cancer: Eli Lilly and Company Merck Sharp & Dohme LLC: January 16 2024: Phase 1 dメルカリNettetEli Lilly and Company. Eudract number. 2024-003270-64. Duration of Study in the UK. 3 years, 0 months, 9 days. ... LY3475070 is an orally available drug that works by … dメニュー 駅Nettet31. okt. 2024 · The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and ... (1-877-285-4559) or 1-317-615-4559 … dモーニングとは